IL3Rα antibody conjugates and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO

8992910

APP PUB NO

20120189540A1

SERIAL NO

13439453

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
STEAMLINE THERAPEUTICS, INC.NEW YORK, NY, US1

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bergstein, Ivan New York, US 30 395

Cited Art Landscape

Patent Info (Count) # Cites Year
 
University of Kentucky Research Foundation (5)
6733743 Methods to impair hematologic cancer progenitor cells and compounds related thereto 43 2001
2003/0039,611 Methods to impair hematologic cancer progenitor cells and compounds related thereto 2 2001
7651678 Methods to impair hematologic cancer progenitor cells and compounds related thereto 4 2004
* 2004/0197,337 Methods to impair hematologic cancer progenitor cells and compounds related thereto 6 2004
2010/0093,003 METHODS TO IMPAIR HEMATOLOGIC CANCER PROGENITOR CELLS AND COMPOUNDS RELATED THERETO 4 2009
 
WASHINGTON UNIVERSITY (1)
5489516 Hybridoma and monoclonal antibody specific for human stem cell factor receptor and methods of use of the monoclonal antibody for detection of stem cell factor receptors 25 1993
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Sep 30, 2018
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 30, 2022
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 30, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00